Cargando…
Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia
BRD4 plays a key role in the regulation of gene transcription and has been identified as an attractive target for cancer treatment. In this study, we designed 26 new compounds by modifying 3-ethyl-benzo[d]isoxazole core with sulfonamides. Most compounds exhibited potent BRD4 binding activities with...
Autores principales: | Zhang, Mao-feng, Luo, Xiao-yu, Zhang, Cheng, Wang, Chao, Wu, Xi-shan, Xiang, Qiu-ping, Xu, Yong, Zhang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905034/ https://www.ncbi.nlm.nih.gov/pubmed/35264812 http://dx.doi.org/10.1038/s41401-022-00881-y |
Ejemplares similares
-
Inhibition of HIV-1 Replication by Isoxazolidine and Isoxazole Sulfonamides
por: Loh, Belinda, et al.
Publicado: (2010) -
Synthesis of some novel coumarin isoxazol sulfonamide hybrid compounds, 3D-QSAR studies, and antibacterial evaluation
por: Esfahani, Sheida Nasr, et al.
Publicado: (2021) -
Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells
por: Zhou, Lixin, et al.
Publicado: (2021) -
5-Methyl-N-[2-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
por: Wang, De-Cai, et al.
Publicado: (2012) -
4-[(2-Hydroxybenzylidene)amino]-N-(5-methylisoxazol-3-yl)benzenesulfonamide: a monoclinic polymorph
por: Ebenezer, Samuel, et al.
Publicado: (2010)